CalciMedica Inc. announced that its Chief Medical Officer, Sudarshan Hebbar, M.D., delivered a plenary presentation at the 30th International Acute Kidney Injury and Continuous Renal Replacement Therapy Conference. The presentation included new data from a post-hoc analysis of the previously completed Phase 2 CARDEA trial of Auxora in severe COVID-19 pneumonia, highlighting Auxora's potential in acute kidney injury (AKI).
The analysis focused on a subset of 38 patients in the CARDEA trial who had AKI at enrollment. In this group, Auxora demonstrated a 62.7% relative reduction in mortality at day 30 compared to placebo, an effect that persisted through day 60. This reduction in mortality in the AKI patient subset exceeded the 56.3% relative reduction observed in the entire CARDEA study population.
Dr. Hebbar emphasized that this post-hoc analysis is particularly relevant because the observed mortality reduction occurred in patients with both kidney failure and respiratory failure, mirroring the intended patient population for CalciMedica's ongoing Phase 2 KOURAGE study. The data provides compelling biological rationale for CRAC channel inhibition as a potential therapeutic mechanism for AKI, reinforcing the promise of Auxora in this critical indication.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.